Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Bradley, Todd, Pollara, Justin, Santra, Sampa, Vandergrift, Nathan, Pittala, Srivamshi, Bailey-Kellogg, Chris, Shen, Xiaoying, Parks, Robert, Goodman, Derrick, Eaton, Amanda, Balachandran, Harikrishnan, Mach, Linh V., Saunders, Kevin O., Weiner, Joshua A., Scearce, Richard, Sutherland, Laura L., Phogat, Sanjay, Tartaglia, Jim, Reed, Steven G., Hu, Shiu-Lok, Theis, James F., Pinter, Abraham, Montefiori, David C., Kepler, Thomas B., Peachman, Kristina K., Rao, Mangala, Michael, Nelson L., Suscovich, Todd J., Alter, Galit, Ackerman, Margaret E., Moody, M. Anthony, Liao, Hua-Xin, Tomaras, Georgia, Ferrari, Guido, Korber, Bette T., Haynes, Barton F.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5472724/
https://ncbi.nlm.nih.gov/pubmed/28593989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms15711
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars